Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1990 Feb;65(2):196–200. doi: 10.1136/adc.65.2.196

Pharmacokinetics of prednisolone in children with nephrosis.

P F Miller 1, C J Bowmer 1, J Wheeldon 1, J T Brocklebank 1
PMCID: PMC1792212  PMID: 2317067

Abstract

The pharmacokinetics of prednisolone given intravenously were studied in 11 children with relapsed steroid responsive nephrotic syndrome, and four control subjects. The clearance of both total and unbound drug was decreased in these children and the unbound fraction of the drug in plasma was significantly correlated with the degree of hypoalbuminaemia. We conclude that changes in the clearance of prednisolone and altered protein binding might account for some of the variability in both therapeutic responses and the incidence of toxicity in patients treated with standard dosage regimens.

Full text

PDF
196

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gatti G., Perucca E., Frigo G. M., Notarangelo L. D., Barberis L., Martini A. Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. Br J Clin Pharmacol. 1984 Apr;17(4):423–431. doi: 10.1111/j.1365-2125.1984.tb02367.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Green O. C., Winter R. J., Kawahara F. S., Phillips L. S., Lewy P. R., Hart R. L., Pachman L. M. Plasma levels, half-life values, and correlation with physiologic assays for growth and immunity. J Pediatr. 1978 Aug;93(2):299–303. doi: 10.1016/s0022-3476(78)80529-0. [DOI] [PubMed] [Google Scholar]
  3. Hartley R., Brocklebank J. T. Determination of prednisolone in plasma by high-performance liquid chromatography. J Chromatogr. 1982 Nov 12;232(2):406–412. doi: 10.1016/s0378-4347(00)84181-x. [DOI] [PubMed] [Google Scholar]
  4. Leisti S., Koskimies O. Risk of relapse in steroid-sensitive nephrotic syndrome: effect of stage of post-prednisone adrenocortical suppression. J Pediatr. 1983 Oct;103(4):553–557. doi: 10.1016/s0022-3476(83)80582-4. [DOI] [PubMed] [Google Scholar]
  5. Lewis G. P., Jusko W. J., Graves L., Burke C. W. Prednisone side-effects and serum-protein levels. A collaborative study. Lancet. 1971 Oct 9;2(7728):778–780. doi: 10.1016/s0140-6736(71)92738-3. [DOI] [PubMed] [Google Scholar]
  6. Milsap R. L., Jusko W. J. Binding of prednisolone to alpha 1-acid glycoprotein. J Steroid Biochem. 1983 Feb;18(2):191–194. doi: 10.1016/0022-4731(83)90087-0. [DOI] [PubMed] [Google Scholar]
  7. Rane A., Wilson J. T. Clinical pharmacokinetics in infants and children. Clin Pharmacokinet. 1976;1(1):2–24. doi: 10.2165/00003088-197601010-00002. [DOI] [PubMed] [Google Scholar]
  8. SLAUNWHITE W. R., LOCKIE G. N., BACK N., SANDBERG A. A. Inactivity in vivo of transcortin-bound cortisol. Science. 1962 Mar 23;135(3508):1062–1063. doi: 10.1126/science.135.3508.1062. [DOI] [PubMed] [Google Scholar]
  9. Sedman A. J., Wagner J. G. CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci. 1976 Jul;65(7):1006–1010. doi: 10.1002/jps.2600650713. [DOI] [PubMed] [Google Scholar]
  10. Steele W. H., Hawksworth G. M., Barber H. E. The binding of prednisolone in human serum and to recrystallized human albumin in vitro. Br J Clin Pharmacol. 1982 Nov;14(5):667–672. doi: 10.1111/j.1365-2125.1982.tb04954.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ueda N., Chihara M., Kawaguchi S., Niinomi Y., Nonoda T., Matsumoto J., Ohnishi M., Yasaki T. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. J Pediatr. 1988 Jan;112(1):122–126. doi: 10.1016/s0022-3476(88)80136-7. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES